Since AbbVie Inc.'s (NYSE: ABBV)inception, investors have been fretting about the eventual demise of its lead drug, Humira. The aging blockbuster has slowed down a bit during the first three months of the year, but the rest of the company's product lineup stepped up and delivered.
AbbVie's First Quarter: Can We Quit Worrying About Humira Now?
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться